[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-406541-105":59,"doc-detail-406541-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","impact-of-teduglutide-on-pediatric-short-bowel-syndrome-systematic-review-and-trial-sequential-meta-analysis","Impact of teduglutide on pediatric short bowel syndrome - systematic review and trial sequential meta-analysis","","Background: Pediatric short bowel syndrome (SBS) creates substantial management challenges, and teduglutide is a promising therapy, yet comprehensive pediatric safety evidence remains limited. Aim: Assess effects of teduglutide on infection and gastrointestinal adverse events in pediatric SBS through systematic review and meta-analysis. Methods: Following PRISMA 2009 and PROSPERO registration, randomized controlled trials were searched and assessed for bias, with meta-analyses, trial sequential analysis, and GRADE evaluation. Results: Three RCTs (n=115) showed no significant infection or GI adverse-event risk differences; certainty was moderate. Conclusion: Teduglutide did not increase risk, while small sample sizes warrant larger studies.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-teduglutide-on-pediatric-short-bowel-syndrome-systematic-review-and-trial-sequential-meta-analysis/406541/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-teduglutide-on-pediatric-short-bowel-syndrome-systematic-review-and-trial-sequential-meta-analysis/406541.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s primary purpose regarding teduglutide in pediatric short bowel syndrome?","Question",{"text":112,"@type":113},"To evaluate the impact of teduglutide on infection and gastrointestinal adverse events in pediatric SBS using a systematic review and meta-analysis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many randomized controlled trials and participants were included, and what did the pooled results show?",{"text":117,"@type":113},"Three RCTs involving 115 pediatric patients were included; pooled analysis found no statistically significant difference in infection events between teduglutide and control groups.",{"name":119,"@type":110,"acceptedAnswer":120},"Were there differences in secondary gastrointestinal adverse outcomes between the teduglutide and control groups?",{"text":121,"@type":113},"No statistically significant differences were reported across multiple secondary outcomes (e.g., upper respiratory tract infection, catheter site infection, vomiting, abdominal pain, nausea, diarrhea, and abdominal distension).",{"name":123,"@type":110,"acceptedAnswer":124},"What limitation did the authors note and what future research was suggested?",{"text":125,"@type":113},"Small sample sizes limited conclusions; larger studies are needed to confirm safety and outcomes.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},406541,1790901377,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":4},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","| W | J | G | S | World Journal of\u003Cbr>Gastrointestinal Surgery |\n| --- | --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Gastrointest Surg 2025 December 27; 17(12): 112685  \nDOI: 10.4240/wjgs.v17.i12.112685 ISSN 1948-9366 (online)  \nMETA-ANALYSIS  \nImpact of teduglutide on pediatric short bowel syndrome: A systematic review and trial sequential meta-analysis  \nPan Jiao, Zhong-Jing Zhang, Ying Jiang, Jun Zhou, Ke-Heng Deng, Wen-Xiang Zhu, Xiang-You Zhao, ZhaoKun Guo  \nSpecialty type: Gastroenterology and hepatology  \nProvenance and peer review:  \nUnsolicited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade B, Grade C  \nNovelty: Grade A, Grade C  \nCreativity or Innovation: Grade A, Grade C  \nScientific Significance: Grade A, Grade C  \nP-Reviewer: Dharmaraj R, Associate Professor, United States; Li J, PhD, Academic Fellow, Senior Researcher, China  \nReceived: August 4, 2025  \nRevised: September 24, 2025  \nAccepted: October 22, 2025  \nPublished online: December 27, 2025  \nProcessing time: 144 Days and 16.5 Hours  \nPan Jiao, Zhong-Jing Zhang, Ying Jiang, Jun Zhou, Ke-Heng Deng, Wen-Xiang Zhu, Xiang-You Zhao, Zhao-Kun Guo, Department of Pediatric Surgery, Yichang Central People's Hospital Affiliated to China Three Gorges University, Yichang 443003, Hubei Province, China  \nCorresponding author: Zhao-Kun Guo, MD, Department of Pediatric Surgery, Yichang Central People's Hospital Affiliated to China Three Gorges University, No. 183 Yiling Road, Yichang 443003, Hubei Province, [China.](China. 12893437@qq.com)[ 12893437@qq.com](China. 12893437@qq.com)  \nAbstract  \nBACKGROUND  \nPediatric short bowel syndrome (SBS) poses management challenges, and teduglutide is a potential therapy. However, comprehensive data on its pediatric safety are lacking.  \nAIM  \nTo evaluate the impact of teduglutide on infection and gastrointestinal adverse events in pediatric SBS patients via systematic review and meta-analysis.  \nMETHODS  \nFollowing PRISMA 2009 guidelines and PROSPERO registration, we searched PubMed, Web of Science, and EMBASE for randomized controlled trials (RCTs)(pediatric SBS patients ≤ 18 years; teduglutide vs placebo/standard care) . Two reviewers screened studies, extracted data, and assessed bias (ROB2) . Metaanalyses used RevMan 5.4 (Mantel-Haenszel method, random-effects if I2 ≠ 0) . Trial sequential analysis and GRADE were applied.  \nRESULTS  \nThree RCTs involving 115 pediatric patients were included. Pooled analysis revealed no statistically significant differences between the teduglutide and control groups for the primary outcome of infection events [RR = 0.83; (95%CI: 0.44- 1.56); P = 0.57; I2 = 0%; 2 studies, n = 55] . Similarly, no significant differences were found for secondary outcomes: Upper respiratory tract infection [RR = 0.68;(95%CI: 0.32-1.47); P = 0.33; I2 = 0%], catheter site infection [RR = 1.86; (95%CI: 0.23-14.78); P = 0.56; I2 = 0%], vomiting [RR = 1.35; (95%CI: 0.10-18.23); P = 0.82; I2 = 72%], abdominal pain [RR = 2.47; (95%CI: 0.50-12.16); P = 0.27; I2 = 0%], nausea [RR = 1.31; (95%CI: 0.24-7.22); P = 0.75; I2 = 0%], diarrhea [RR = 1.02; (95%CI: 0.23- 4.43); P = 0.98; I2 = 0%], and abdominal distension [RR = 1.49; (95%CI: 0.18-12.35);  \n WJGS  [https://www.wjgnet.com](https://www.wjgnet.com) 1 December 27, 2025  Volume 17  Issue 12   \nJiao P et al. Teduglutide in peds SBS: Meta-analysis  \nP = 0.71; I2 = 0%]. The overall certainty of evidence assessed by GRADE was moderate.  \nCONCLUSION  \nTeduglutide does not increase infection or gastrointestinal adverse event risk in pediatric SBS, but small sample sizes limit conclusions. Larger studies are needed.  \nKey Words: Teduglutide; Pediatric short bowel syndrome; Systematic review; Meta-analysis; Trial sequential analysis; Safety profile  \n©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights re","cbCaijj71FZjfq9k","https://ap.wps.com/l/cbCaijj71FZjfq9k","pdf",2640403,"English","# Abstract\n## Background\n## Aim\n## Methods\n## Results\n## Conclusion\n# Core Tip","[{\"question\":\"What was the study’s primary purpose regarding teduglutide in pediatric short bowel syndrome?\",\"answer\":\"To evaluate the impact of teduglutide on infection and gastrointestinal adverse events in pediatric SBS using a systematic review and meta-analysis.\"},{\"question\":\"How many randomized controlled trials and participants were included, and what did the pooled results show?\",\"answer\":\"Three RCTs involving 115 pediatric patients were included; pooled analysis found no statistically significant difference in infection events between teduglutide and control groups.\"},{\"question\":\"Were there differences in secondary gastrointestinal adverse outcomes between the teduglutide and control groups?\",\"answer\":\"No statistically significant differences were reported across multiple secondary outcomes (e.g., upper respiratory tract infection, catheter site infection, vomiting, abdominal pain, nausea, diarrhea, and abdominal distension).\"},{\"question\":\"What limitation did the authors note and what future research was suggested?\",\"answer\":\"Small sample sizes limited conclusions; larger studies are needed to confirm safety and outcomes.\"}]","Impact of teduglutide on pediatric short bowel syndrome - systematic review and trial sequential meta-analysis | PDF",1790566314,25]